Table 4.
Treatment details
| <60 group (N = 286) | ≥60 group (N = 72) | p-value | |
|---|---|---|---|
| Initial therapy | 0.160 | ||
| Prednisone and azathioprine | 235 (82%) | 57 (80%) | |
| Prednisone | 29 (10%) | 5 (7%) | |
| No medication | 7 (2%) | 5 (7%) | |
| Budesonide and azathioprine | 5 (2%) | 1 (1%) | |
| Budesonide | 4 (2%) | 0 (0%) | |
| Othera | 6 (2%) | 4 (5%) | |
| Maintenance therapy | 0.208 | ||
| Prednisone and azathioprine | 99 (35%) | 19 (26%) | |
| Azathioprine | 57 (20%) | 18 (25%) | |
| No medication | 27 (9%) | 11 (15%) | |
| Prednisone | 23 (8%) | 7 (10%) | |
| Budesonide and azathioprine | 17 (6%) | 3 (4%) | |
| Otherb | 63 (22%) | 14 (20%) | |
| Side effects | 118 (41%) | 28 (39%) | 0.789 |
| Corticosteroids | |||
| Osteoporosis | 35 (12%) | 5 (7%) | 0.294 |
| Cushingoid changes | 29 (10%) | 4 (6%) | 0.360 |
| Steroid induced diabetes | 15 (5%) | 12 (16%) | 0.004 |
| Immunomodulator | |||
| Leucopenia | 13 (5%) | 3 (4%) | 1.000 |
| Gastro-intestinal symptoms | 12 (4%) | 2 (3%) | 0.744 |
| Otherc | 18 (6%) | 4 (6%) | |
Number (percentage)
aPrednisone and 6-mercapopurine, ursdeoxycholic acid, prednisone and azathioprine and ursochol, prednisone and ursodeoxycholic acid, infliximab, azathioprine.
b23 combinations of mycophenolat mofetil, budesonide, 6-mercaptopurine, thioguanine, cyclosporine, ursodeoxycholic acid, prednisone, tacrolimus and azathioprine.
cHair loss, arthralgia, liver enzyme elevations and rash.
Bold is significant